Literature DB >> 14532330

Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.

Maria Elena Fernández-Sánchez1, Olga Criado-García, Karen E Heath, Belén García-Fojeda, Iria Medraño-Fernández, Pilar Gomez-Garre, Pascual Sanz, José María Serratosa, Santiago Rodríguez de Córdoba.   

Abstract

Progressive myoclonus epilepsy of Lafora type (LD, MIM 254780) is a fatal autosomal recessive disorder characterized by the presence of progressive neurological deterioration, myoclonus, epilepsy and polyglucosan intracellular inclusion bodies, called Lafora bodies. Lafora bodies resemble glycogen with reduced branching, suggesting an alteration in glycogen metabolism. Linkage analysis and homozygosity mapping localized EPM2A, a major gene for LD, to chromosome 6q24. EPM2A encodes a protein of 331 amino acids (named laforin) with two domains, a dual-specificity phosphatase domain and a carbohydrate binding domain. Here we show that, in addition, laforin interacts with itself and with the glycogen targeting regulatory subunit R5 of protein phosphatase 1 (PP1). R5 is the human homolog of the murine Protein Targeting to Glycogen, a protein that also acts as a molecular scaffold assembling PP1 with its substrate, glycogen synthase, at the intracellular glycogen particles. The laforin-R5 interaction was confirmed by pull-down and co-localization experiments. Full-length laforin is required for the interaction. However, a minimal central region of R5 (amino acids 116-238), including the binding sites for glycogen and for glycogen synthase, is sufficient to interact with laforin. Point-mutagenesis of the glycogen synthase-binding site completely blocked the interaction with laforin. The majority of the EPM2A missense mutations found in LD patients result in lack of phosphatase activity, absence of binding to glycogen and lack of interaction with R5. Interestingly, we have found that the LD-associated EPM2A missense mutation G240S has no effect on the phosphatase or glycogen binding activities of laforin but disrupts the interaction with R5, suggesting that binding to R5 is critical for the laforin function. These results place laforin in the context of a multiprotein complex associated with intracellular glycogen particles, reinforcing the concept that laforin is involved in the regulation of glycogen metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14532330     DOI: 10.1093/hmg/ddg340

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  38 in total

1.  Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.

Authors:  Erica Tiberia; Julie Turnbull; Tony Wang; Alessandra Ruggieri; Xiao-Chu Zhao; Nela Pencea; Johan Israelian; Yin Wang; Cameron A Ackerley; Peixiang Wang; Yan Liu; Berge A Minassian
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

2.  The laforin-malin complex negatively regulates glycogen synthesis by modulating cellular glucose uptake via glucose transporters.

Authors:  Pankaj Kumar Singh; Sweta Singh; Subramaniam Ganesh
Journal:  Mol Cell Biol       Date:  2011-11-28       Impact factor: 4.272

Review 3.  Lafora disease: epidemiology, pathophysiology and management.

Authors:  Thomas S Monaghan; Norman Delanty
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

4.  Glycogen metabolism in tissues from a mouse model of Lafora disease.

Authors:  Wei Wang; Hannes Lohi; Alexander V Skurat; Anna A DePaoli-Roach; Berge A Minassian; Peter J Roach
Journal:  Arch Biochem Biophys       Date:  2006-11-03       Impact factor: 4.013

5.  A Second Gene for Lafora Disease.

Authors:  Robyn Wallace
Journal:  Epilepsy Curr       Date:  2004-03       Impact factor: 7.500

6.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.

Authors:  Matthew S Gentry; Carolyn A Worby; Jack E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-01       Impact factor: 11.205

Review 7.  Advances in lafora progressive myoclonus epilepsy.

Authors:  Antonio V Delgado-Escueta
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

8.  AMP-activated protein kinase phosphorylates R5/PTG, the glycogen targeting subunit of the R5/PTG-protein phosphatase 1 holoenzyme, and accelerates its down-regulation by the laforin-malin complex.

Authors:  Santiago Vernia; M Carmen Solaz-Fuster; José Vicente Gimeno-Alcañiz; Teresa Rubio; Luisa García-Haro; Marc Foretz; Santiago Rodríguez de Córdoba; Pascual Sanz
Journal:  J Biol Chem       Date:  2009-01-26       Impact factor: 5.157

9.  Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.

Authors:  Vincent S Tagliabracci; Jean Marie Girard; Dyann Segvich; Catalina Meyer; Julie Turnbull; Xiaochu Zhao; Berge A Minassian; Anna A Depaoli-Roach; Peter J Roach
Journal:  J Biol Chem       Date:  2008-10-13       Impact factor: 5.157

Review 10.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.